Ibuprofeno Genfar

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ibuprofeno Genfar

Property Description
Active ingredient Ibuprofen
Form Oral Tablet, Capsule, Oral Suspension
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic compound (Propionic acid derivative)

What Type of Medicine is Ibuprofeno Genfar?

Ibuprofeno Genfar is a recognized pharmaceutical preparation whose active ingredient is Ibuprofen, categorized within the Nonsteroidal Anti-Inflammatory Drug (NSAID) class. This medication is a single-ingredient product, chemically identified as a propionic acid derivative and a synthetic compound. The classification as an NSAID is universally recognized, and the drug is widely used as an essential component of healthcare globally. This confirms its utility for a broad range of symptoms that benefit from pain and fever control.

Composition, Origin, and Available Forms

The active constituent, Ibuprofen, is a chemically manufactured entity, confirming its synthetic origin. Ibuprofeno Genfar is manufactured for oral administration and is available in multiple common oral dosage forms for systemic action, including the tablet, capsule, and the liquid oral suspension. The composition of these forms is rigorously standardized; the final dose contains the active drug alongside necessary inactive excipients and vehicles required to deliver the drug effectively to the digestive tract. The medication works by blocking the body's production of substances that cause inflammation.

General Purpose and Core Physiological Actions

The general purpose of the medicine is to provide symptomatic relief by moderating the body’s adverse physical responses to irritation and discomfort, a function clinically recognized across numerous pharmacological studies. This is achieved through the compound's basic function as an Analgesic, an Antipyretic, and an Anti-inflammatory Agent. The combined utility of this NSAID is critical, making it suitable for scenarios like managing the discomfort associated with a moderate headache or reducing a fever. The ability to suppress the pain response, mitigate swelling, and lower body temperature means the drug serves the general purpose of comprehensive relief from disturbances characterized by these three elements.

Regulatory References

  1. World Health Organization Model List of Essential Medicines - Ibuprofen
  2. Ibuprofen: MedlinePlus Drug Information

What side effects are possible with Ibuprofeno Genfar?

Serious Safety Warnings

Ibuprofeno Genfar, as a Nonsteroidal Anti-inflammatory Drug (NSAID), carries mandatory warnings concerning potentially life-threatening risks, even in the absence of initial symptoms. These adverse reactions are dose- and duration-dependent, meaning the risk may be higher with larger amounts or extended use.

  • Cardiovascular Thrombotic Events: NSAIDs increase the risk of serious, and possibly fatal, cardiovascular events, including Myocardial Infarction (heart attack) and Stroke. This risk can occur early in treatment, and the drug is contraindicated for use just before or after Coronary Artery Bypass Graft (CABG) surgery.
  • Gastrointestinal Bleeding: NSAIDs can cause serious gastrointestinal adverse events, such as inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which may be fatal. This risk is greater for the elderly, those with a history of ulcers or bleeding problems, and those taking blood-thinning or steroid medication.

Other Safety Considerations

Regulatory documents highlight several other important areas for caution and monitoring:

  • Allergic Reactions: Severe hypersensitivity reactions, including facial swelling, asthma (wheezing), hives, and shock, may occur, especially in individuals allergic to aspirin or other NSAIDs.
  • Renal and Hepatic Effects: Use may lead to kidney problems (renal impairment) or, less commonly, liver damage.
  • Pregnancy: The use of ibuprofen is highly restricted from 20 weeks gestation onward due to the risk of fetal renal dysfunction leading to low amniotic fluid (oligohydramnios) and potential complications for the unborn child.

Patients should stop use and seek immediate medical attention if they experience symptoms of stomach bleeding (vomiting blood, black or bloody stools), or signs of a heart attack or stroke (chest pain, weakness on one side of the body, slurred speech).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Ibuprofeno Genfar requires immediate medical attention. Officially documented manifestations of acute overdose range from mild symptoms to severe, life-threatening outcomes. Due to the potential for delayed complications, management is uniformly described as symptomatic and supportive, as no specific antidote is known for acute Ibuprofen toxicity.

Documented Overdose Manifestations

Officially recognized clinical signs and symptoms, as described in regulatory documents, include gastrointestinal distress (nausea, vomiting, abdominal pain), Central Nervous System effects (drowsiness, headache, confusion, tinnitus), and cardiovascular changes (hypotension, tachycardia).

Severe Outcomes and Emergency Action

Serious or life-threatening outcomes documented in regulatory sources include progression to coma, generalized convulsions (seizures), acute renal failure, and severe gastrointestinal bleeding or perforation. Immediate emergency assistance is required if the affected individual collapses, has a seizure, or experiences difficulty breathing.

Monitoring and Population Considerations

Individuals who have ingested an excessive amount, even if asymptomatic with normal vital signs, must be observed for a minimum of four to six hours. The official labeling notes that elderly patients are at an increased risk for severe gastrointestinal events, and high-dose exposure (e.g., above 400 mg/kg) in the pediatric population is a factor requiring hospitalization.

Therapeutic Uses of Ibuprofeno Genfar

What Ibuprofeno Genfar Treats: Main Uses and Benefits

The medication is used to provide symptomatic relief across three core therapeutic domains, addressing symptoms related to physical discomfort and heightened physiological activity. It is commonly used across conditions presenting with acute episodes where additional symptomatic support is needed.

Pain, Inflammation, and Fever Relief

Ibuprofeno Genfar is relevant in clinical settings marked by heightened inflammatory symptoms and pain, often applied during phases when symptoms become more noticeable. It helps address symptom clusters that may become intense or disruptive, such as headache, toothache, menstrual cramps (dysmenorrhea), and the pain, stiffness, and swelling associated with conditions like rheumatoid arthritis and osteoarthritis. It is also commonly used to help with fever and general body aches linked to the common cold or flu.

“A central benefit of this medication is its role in easing the overall symptom load related to pain, inflammation, and high temperature, which may contribute to improved comfort during periods of heightened symptoms.”

This supportive relief may assist with maintaining functional stability and helps patients during difficult episodes by easing distress.

Quick Fact: Relief for Acute Discomfort
Ibuprofeno Genfar is commonly used when short-term symptomatic assistance is appropriate during episodic pain like headaches and acute dental pain.

Regulatory References

  1. DailyMed (NIH National Library of Medicine) drug label

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Ibuprofeno Genfar

This information reflects official regulatory statements regarding population eligibility and contraindications for ibuprofen use.


Populations for Whom Use is Prohibited (Contraindicated)

Use of this medicine is strictly prohibited for individuals with the following conditions:

  • Hypersensitivity (allergic reaction) to ibuprofen, aspirin, or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs).
  • Active or recurrent peptic ulcer/bleeding or a history of gastrointestinal bleeding/perforation related to previous NSAID therapy.
  • Severe heart failure (NYHA Class IV), severe renal failure, or severe hepatic failure.
  • The last trimester of pregnancy (due to risk of harm to the fetus and complications during delivery).
  • Conditions involving an increased tendency to bleeding.

Use Requiring Special Consideration

Use is generally established for adults and adolescents (ge 12 years). However, the medicine should be used with caution or is not recommended for certain populations, often at high doses (2400 mg/day):

  • Elderly patients (start at the lowest effective dose due to increased risk of side effects).
  • Patients with uncontrolled hypertension or heart failure (NYHA Class II-III).
  • Women attempting to conceive (due to potential for impaired fertility).
  • Children under 12 years (consult a healthcare provider).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ibuprofeno Genfar documents several interaction patterns, primarily defined by the potential for additive risk and altered drug exposure. Formal Prohibitions exist for co-administration with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, and with aspirin at a daily dose above 75 mg. The use of this medication is also formally restricted for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Clinically significant Exposure-Modifying Interactions occur with several medications due to reduced renal clearance. Co-administration may increase plasma concentrations of Lithium and reduce the clearance of Methotrexate, leading to accumulation risks. Furthermore, Ibuprofen may reduce the antihypertensive or diuretic effects of medications like ACE Inhibitors.

Pharmacodynamic interactions increase the documented risk of serious gastrointestinal bleeding when co-administered with Anticoagulants (e.g., Warfarin), SSRIs, or Oral Corticosteroids. A specific Administration Timing condition is mandated for patients taking low-dose Aspirin for cardioprotection: Ibuprofen must be administered at least 8 hours before or 30 minutes after the Aspirin dose to mitigate interference. Regulatory information also notes that Elderly patients have an increased risk and severity of adverse reactions. The consumption of three or more alcoholic drinks daily is documented to increase the risk of GI bleeding when combined with this product.

Mechanism of Action

How Ibuprofeno Genfar Works

The action of Ibuprofeno Genfar is defined by a primary mechanism of enzyme inhibition that modulates the body's physiological signaling pathways related to nociceptive input and hypothalamic temperature regulation.


Molecular Control via Cyclooxygenase Enzyme Blockade

The active ingredient, Ibuprofen, works as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzyme family (COX-1 and COX-2). This interaction blocks the critical molecular step in the arachidonic acid cascade, preventing the synthesis of prostanoids such as PGE2. This chemical blockade directly modifies key inflammatory and central thermal signaling mediators.


️ Dual Modulation of Peripheral and Central Systems

Suppressing PGE2 production affects peripheral sensitization of pain-sensing nerves and the hypothalamic thermal set-point in the central nervous system (CNS). This leads to a reduction in nerve sensitivity to stimuli and supports the readjustment of the body’s core temperature regulator. This dual action engages both local and systemic pathways that result in altered prostanoid-mediated signal propagation.


️ Mechanistic Constraints of Non-Selectivity

The mechanism is functionally constrained by its non-selective action, which extends to COX-1. COX-1 synthesizes constitutive prostaglandins that maintain essential protective functions, such as gastric mucosal integrity. Consequently, the drug’s action on regulating prostanoid-driven responses via COX-2 inhibition is mechanistically coupled with an interference in homeostatic pathways regulated by COX-1.

Dosage and Administration Information

Ibuprofeno Genfar is an oral medicine whose administration is governed by the principle of using the lowest effective dosage for the shortest duration necessary to achieve symptomatic control. The medication is prepared for systemic action and is available in common oral forms, including tablets, capsules, and oral suspension.

Standard Dosing and Frequency

For non-prescription (OTC) use, the standard single dose is typically 200 mg to 400 mg and should be repeated every 4 to 6 hours as needed. Prescription-strength use may involve individual doses up to 800 mg. Established guidelines include strict maximum daily doses: 1,200 mg for OTC regimens and 3,200 mg for prescription regimens, with use requiring administration in divided portions throughout the day.

Administration Conditions and Duration

The oral dose may be taken with food or milk to potentially mitigate gastrointestinal symptoms, though intake on an empty stomach does not affect overall drug absorption. The liquid oral suspension requires the container to be shaken prior to precise dose measurement. Maximum duration limits for self-treatment are generally three days for fever and ten days for pain. Treatment for chronic conditions, such as arthritis, is often initiated at a lower dose and may be assessed after two weeks to determine the need for adjustment.

Population-Specific Rules

Administration rules for specific patient groups are also defined. Dosing for pediatric patients (ages 6 months to 12 years) is determined by body weight, calculated typically in the range of 5 to 10 mg/kg per dose. Older adults are advised to commence treatment at the lowest effective dose due to increased physiological sensitivity.

Recent Clinical Evidence

The clinical evidence for Ibuprofeno Genfar, which contains the active ingredient Ibuprofen, is available and centers primarily on the symptomatic management of pain, inflammation, and fever. The research base is comprised mainly of Randomized Controlled Trials (RCTs) and Systematic Reviews referenced by major health authorities. The findings describe group patterns, not individual predictions or personal outcomes.

Evidence for Symptom Relief in Acute Pain

Research examined studies related to physical discomfort in acute episodes, such as headache, dental pain, and musculoskeletal injuries. These studies primarily included Adult Patients and relied on short-term RCTs. Researchers evaluated outcomes related to physical discomfort and the need for Rescue Analgesia. Studies monitored outcomes over short intervals, with most follow-up focused on the first 24 hours after a dose. Long-term effects on acute pain management are not typically characterized, and comparative evidence is limited against all available short-term pain relievers across the full spectrum of acute conditions.

Evidence for Antipyretic Use and Fever Control

The active ingredient was evaluated in conditions involving periods of heightened symptoms, specifically for outcomes related to systemic imbalance, such as fever. This research included RCTs and Systematic Reviews where primary outcomes were studied for changes in Body Temperature in both Adult Patients and Pediatric Patients. Studies reported how symptoms evolved, describing patterns of short-term temperature change observed during the study period. Despite the available evidence, data for certain sensitive subgroups, particularly very young infants, remain insufficient, and research is ongoing.

Evidence for Managing Chronic Inflammatory Symptoms

The research base includes Phase II/III RCTs and large-scale Observational Studies that examined the active ingredient in conditions associated with chronic inflammatory states like Osteoarthritis (OA) and Rheumatoid Arthritis (RA). These studies monitored changes in functional measures over periods up to several months. The available long-term safety data that regulators use are largely derived from patients receiving the highest studied daily dosages for extended periods, meaning that data related to lower-dose, long-term use are not fully established.

Key Studies & References

  1. WHO Model List of Essential Medicines - Ibuprofen entry/context
  2. Ibuprofen (oral route) - MedlinePlus Drug Information (General Evidence and Indication Context)
  3. Label: IBUPROFEN tablet - DailyMed (NIH/NLM Drug Label Information)

Frequently Asked Questions (FAQ)

Common questions about Ibuprofeno Genfar (FAQ)

Q: Is Ibuprofeno Genfar the same kind of medicine as acetaminophen?

A: No, these medicines belong to different classes. According to regulatory documents, Ibuprofen (the active ingredient in Ibuprofeno Genfar) is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Acetaminophen (Paracetamol) is classified differently as an analgesic and antipyretic but is not considered an NSAID because it works through a different mechanism.


Q: How quickly do people usually feel the effects of Ibuprofeno Genfar?

A: Official pharmacological data indicates that the active ingredient, Ibuprofen, generally reaches its peak concentration in the bloodstream approximately one to two hours after a dose is taken. This time frame is often associated with when effects may begin to be noted, though individual response can vary.


Q: What are the most common side effects mentioned in studies about Ibuprofeno Genfar?

A: Regulatory documents list several common side effects, primarily involving the digestive system and central nervous system. These frequently documented issues include dyspepsia (indigestion), nausea, stomach pain, heartburn, headache, and dizziness.


Q: Does Ibuprofeno Genfar have interactions with other common cold medicines?

A: Yes, official safety warnings strictly prohibit combining Ibuprofeno Genfar with any other Nonsteroidal Anti-Inflammatory Drug (NSAID). Many over-the-counter cold and flu combination medicines contain NSAIDs. Patients are generally advised to review the active ingredients of other medicines to ensure they do not contain other NSAIDs.


Q: Can Ibuprofeno Genfar cause drowsiness or affect alertness?

A: Official product information notes that certain central nervous system effects are documented among the possible adverse reactions. These include reports of dizziness and fatigue (tiredness), which may potentially affect a person's level of alertness.


Q: What is the difference between Ibuprofeno Genfar and other ibuprofen brands?

A: Ibuprofeno Genfar is a pharmaceutical preparation that contains the active ingredient Ibuprofen. Regulatory guidance confirms that the generic ingredient is the same as that found in common branded products. While the active ingredient is identical, the inactive ingredients (excipients and vehicles) used in the formulation may vary between different brands.


Q: Is Ibuprofeno Genfar considered generally safe for short-term use?

A: Regulatory guidance emphasizes that the medication is intended for use at the lowest effective dose for the shortest duration necessary for symptomatic relief. While this limits duration, the mandatory warnings for serious cardiovascular and gastrointestinal events are considered applicable throughout the entire treatment period, regardless of length.


Q: Can Ibuprofeno Genfar affect lab test results?

A: Official medical information has documented limited evidence suggesting that the active ingredient may interfere with the results of certain in vitro diagnostic tests. Studies have noted potential interference with certain laboratory tests, but the overall clinical importance of this effect is typically not detailed in standard patient information.


Q: What are the initial signs of an interaction with Ibuprofeno Genfar that people should look out for?

A: Official patient information describes that serious adverse events may require immediate medical attention if experienced. These include symptoms of severe gastrointestinal bleeding (such as vomiting blood or black, tarry stools) or signs of a serious cardiovascular event (such as chest pain or weakness on one side of the body).


Q: Can Ibuprofeno Genfar be taken by people with asthma?

A: Ibuprofen is strictly contraindicated (prohibited) for use in patients who have aspirin-sensitive asthma. This is because these individuals have a high risk of experiencing a severe allergic reaction, such as bronchospasm (wheezing). Even when there is no known aspirin sensitivity, regulatory documents indicate that individuals with a history of asthma are generally advised to use the medication with caution.


Q: Is it described in official documents as being effective for migraines?

A: Official regulatory documents approve Ibuprofen for the relief of general headache and other types of mild-to-moderate pain. While some clinical research has examined the active ingredient in the context of acute migraines, the official labels confirm the primary indication is for general headache relief and mild-to-moderate pain.


Q: What are the potential effects of Ibuprofeno Genfar on pregnant or breastfeeding women, according to official warnings?

A: Use of the medication is strictly prohibited during the last trimester of pregnancy due to the risk of harm to the unborn child. Official studies for breastfeeding indicate that Ibuprofen passes into breast milk in very low concentrations and is considered unlikely to adversely affect a breastfed infant.


Q: What is the half-life of Ibuprofeno Genfar, as reported in pharmacologic data?

A: Pharmacologic data detailed in official documents reports that the serum half-life of the active ingredient, Ibuprofen, is approximately 1.8 to 2.0 hours. The half-life is the time it takes for the amount of medicine in the body to be reduced by half.


Q: Can Ibuprofeno Genfar interact with herbal supplements?

A: The product label typically does not list specific herbal products, but caution is generally advised when combining Ibuprofen with supplements that may have blood-thinning effects. Combining them may carry a potential for an increased risk of bleeding.


Q: Is Ibuprofeno Genfar the same active ingredient as what is found in Advil or Motrin?

A: Yes. According to equivalence statements referenced in regulatory data, Ibuprofeno Genfar, Advil, and Motrin all contain the identical active pharmaceutical ingredient: Ibuprofen.


Q: Is there evidence to support the use of Ibuprofeno Genfar for menstrual pain?

A: Yes, official regulatory documents confirm that Ibuprofen has an approved indication for the treatment of dysmenorrhea, which is the medical term for painful menstruation or menstrual cramps.

How should Ibuprofeno Genfar be stored and disposed of?

The official regulatory requirements for Ibuprofen preparations define specific conditions to maintain product stability and ensure public safety.

Storage Conditions

Labeled Storage Temperature 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature)
Protection Requirements Store away from excessive heat and moisture. Liquid forms should not be allowed to freeze.
Container Rules Must be kept in the original container with the cap tightly closed. The product should be discarded if the seal is broken or missing.
Child Safety The medication must be kept strictly out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Ibuprofen must be done in accordance with local regulations and requirements. The product should generally not be flushed down the toilet or poured down the sink. Federal guidelines recommend utilizing authorized drug take-back programs or collection sites for proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ibuprofeno Genfar found in:

A-Z Index: